

COSTEM 2021 – Scientific Program

*All program timing in CET*

Thursday, October 21	
14:30-15:00	<i>Industry Meet the Expert session</i>
15:30-17:00	<i>Industry Symposium</i>

Friday, October 22			
Hall A			
09:00-10:45	Session 1: Opening Session		
09:00-09:15	Welcome note: <b>Nicolaus Kröger</b> , Germany; <b>Arnon Nagler</b> , Israel		
09:15-10:00	Controversy: Are CAR T cells the standard treatment for refractory DLBCL? Moderator: <b>Nicolaus Kröger</b> , Germany		
09:15-09:30	Yes: <b>Stephen Schuster</b> , USA		
09:30-09:45	No: <b>Mehdi Hamadani</b> , USA		
09:45-10:00	Discussion		
10:00-10:45	Controversy: Is there a need for allogeneic SCT consolidation in ALL patients post CAR? Moderator: <b>Arnon Nagler</b> , Israel		
10:00-10:15	Yes: <b>Peihua Lu</b> , China		
10:15-10:30	No: <b>Michael Pulsipher</b> , USA		
10:30-10:45	Discussion		
10:45-11:00	<i>Break</i>		
Hall A		Hall B	
11:00-12:30	Session 2: Multiple myeloma I	11:00-12:30	Session 3: Acute myeloid leukemia
11:00-11:45	Controversy: Are CARs better for R/R Myeloma than antibodies? Moderator: <b>Nicolaus Kröger</b> , Germany	11:00-11:45	Controversy: Maintenance post Allo in FLT3+ AML: Is sorafenib the new standard? Moderator: <b>Charles Craddock</b> , UK
11:00-11:15	Yes: <b>Noopur Raje</b> , USA	11:00-11:15	Yes: <b>Andreas Burchert</b> , Germany
11:15-11:30	No: <b>Hermann Einsele</b> , Germany	11:15-11:30	No: <b>Yi-Bin Chen</b> , USA
11:30-11:45	Discussion	11:30-11:45	Discussion
11:45-12:30	Controversy: Still a role of allogeneic SCT as salvage treatment in MM? Moderator: <b>Hermann Einsele</b> , Germany	11:45-12:30	Controversy: Is RIC sufficient in MRD neg. AML patients? Moderator: <b>Arnon Nagler</b> , Israel
		11:45-12:00	Yes: <b>Andreas Bacigalupo</b> , Italy

11:45-12:00	Yes: <b>Gösta Gahrton</b> , Sweden	12:00-12:15	No: <b>Charles Craddock</b> , UK
12:00-12:15	No: <b>Philippe Moreau</b> , France	12:15-12:30	Discussion
12:15-12:30	Discussion		
<b>12:30-13:00</b>	<i>Break – Visit Exhibition</i>		
<b>13:00-14:15</b>	<i>Industry Symposium</i>		
<b>14:15-14:30</b>	<i>Break</i>		
	<b>Hall A</b>		<b>Hall B</b>
<b>14:30-16:00</b>	<b>Session 4: Haploidentical transplant</b>	<b>14:30-16:00</b>	<b>Session 5: Severe aplastic anemia</b>
<b>14:30-15:15</b>	Controversy: Is PTCy the better Haplo approach than ATG? Moderator: <b>Didier Blaise</b> , France	<b>14:30-15:15</b>	Controversy: Does introduction of eltrombopag change transplant indication for sAA? Moderator: <b>Carlo Dufour</b> , Italy
14:30-14:45	Yes: <b>Leonido Luznik</b> , USA	14:30-14:45	Yes: <b>Antonio Risitano</b> , Italy
14:45-15:00	No: <b>He Huang</b> , China	14:45-15:00	No: <b>Regis Peffault de Latour</b> , France
15:00-15:15	Discussion	15:00-15:15	Discussion
<b>15:15-16:00</b>	Controversy: Is GVL stronger in Haplo than in MUD for AML? Moderator: <b>Robert Soiffer</b> , USA	<b>15:15-16:00</b>	Controversy: Do we need ATG/ATLG for GVHD prophylaxis in HLA-identical sibling transplant? Moderator: <b>Francesca Bonifazi</b> , Italy
15:15-15:30	Yes: <b>Nicolaus Kröger</b> , Germany	15:15-15:30	Yes: <b>He Huang</b> , China
15:30-15:45	No: <b>Arnon Nagler</b> , Israel	15:30-15:45	No: <b>Robert Soiffer</b> , USA
15:45-16:00	Discussion	15:45-16:00	Discussion
<b>16:00-16:15</b>	<i>Break</i>		
	<b>Hall A</b>		<b>Hall B</b>
<b>16:15-17:45</b>	<b>Session 6: GVHD I</b>	<b>16:15-17:45</b>	<b>Session 7: Acute lymphocytic leukemia</b>
<b>16:15-17:00</b>	Controversy: Is Ruxolitinib the new standard for second line therapy for cGVHD? Moderator: <b>Daniel Wolff</b> , Germany	<b>16:15-17:00</b>	Controversy: How to bridge relapsed ALL to transplant? Moderator: <b>Dieter Hoelzer</b> , Germany
16:15-16:30	Yes: <b>Hildegard Greinix</b> , Austria	16:15-16:30	Blinatumumab: <b>Renato Bassan</b> , Italy
16:30-16:45	No: <b>Steven Pavletic</b> , USA	16:30-16:45	Inotuzumab: <b>Matthias Stelljes</b> , Germany
16:45-17:00	Discussion	16:45-17:00	Discussion
<b>17:00-17:45</b>	Controversy: Should we perform gut decontamination pre-transplant? Moderator: <b>Steven Pavletic</b> , USA	<b>17:00-17:45</b>	Controversy: Can allogeneic SCT in Ph+ ALL be avoided? Moderator: <b>Matthias Stelljes</b> , Germany
17:00-17:15	Yes: <b>Ernst Holler</b> , Germany	17:00-17:15	Yes: <b>Robin Foa</b> , Italy
17:15-17:30	No: <b>Marcel van den Brink</b> , USA	17:15-17:30	No: <b>Alessandro Rambaldi</b> , Italy
17:30-17:45	Discussion	17:30-17:45	Discussion

**Saturday, October 23**

	Hall A		Hall B
<b>09:30-11:00</b>	<b>Session 8: Myelodysplastic syndrome</b>	<b>09:30-11:00</b>	<b>Session 9: GVHD II</b>
<b>09:30-10:15</b>	Controversy: Does mutation screening impact transplant decisions in MDS in 2020? Moderator: <b>Ibrahim Yakoub-Agha</b> , France	<b>09:30-10:15</b>	Controversy: Is PTCy the better GvHD prophylaxis than ATG in MUD? Moderator: <b>Andreas Bacigalupo</b> , Italy
09:30-09:45	Yes: <b>Marie Robin</b> , France	09:30-09:45	Yes: <b>Mohamad Mohty</b> , France
09:45-10:00	No: <b>Avicahi Shimoni</b> , Israel	09:45-10:00	No: <b>Francesca Bonifazi</b> , Italy
10:00-10:15	Discussion	10:00-10:15	Discussion
<b>10:15-11:00</b>	Controversy: Should novel agents be used for induction prior to transplant in MDS EB1/2? Moderator: <b>Avicahi Shimoni</b> , Israel	<b>10:15-11:00</b>	Controversy: Is Haplo the alternative to MUD in AA? Moderator: <b>Regis Peffault de Latour</b> , France
10:15-10:30	Yes: <b>Uwe Platzbecker</b> , Germany	10:15-10:30	Yes: <b>Mahmoud Aljurf</b> , Saudi Arabia
10:30-10:45	No: <b>Ibrahim Yakoub-Agha</b> , France	10:30-10:45	No: <b>Carlo Dufour</b> , Italy
10:45-11:00	Discussion	10:45-11:00	Discussion
<b>11:00-11:15</b>	<i>Break</i>		
	Hall A		Hall B
<b>11:15-12:45</b>	<b>Session 10: Myelofibrosis</b>	<b>11:15-12:45</b>	<b>Session 11: Multiple myeloma II</b>
<b>11:15-12:00</b>	Controversy: 60y DIPSS intermediate I with <i>ASXL1</i> , <i>EZH2</i> , <i>SRSF2</i> Allo Moderator: <b>Marie Robin</b> , France	<b>11:15-12:00</b>	Controversy: Is there a role for Auto in Amyloidosis in 2021? Moderator: <b>Peter Sonneveld</b> , Netherlands
11:15-11:30	Pro: <b>Nicolaus Kröger</b> , Germany	11:15-11:30	Yes: <b>Stefan Schönland</b> , Germany
11:30-11:45	Con: <b>Francesco Passamonti</b> , Italy	11:30-11:45	No: <b>Giampaolo Merlini</b> , Italy
11:45-12:00	Discussion	11:45-12:00	Discussion
<b>12:00-12:45</b>	Controversy: Early Allo in PMF patient responding to JAK2 inhibitor Moderator: <b>Francesco Passamonti</b> , Italy	<b>12:00-12:45</b>	Controversy: Is double Auto upfront in high-risk MM standard? Moderator: <b>Hartmut Goldschmidt</b> , Germany
12:00-12:15	Pro: <b>Juan Carlos Hernandez-Boluda</b> , Spain	12:00-12:15	Yes: <b>Peter Sonneveld</b> , Netherlands
12:15-12:30	Con: <b>Donal McLornan</b> , UK	12:15-12:30	No: <b>Sergio Giral</b> , USA
12:30-12:45	Discussion	12:30-12:45	Discussion
<b>12:45-13:15</b>	<i>Break and Visit Exhibition</i>		
<b>13:15-14:30</b>	<i>Industry Symposium</i>		
<b>14:30-14:45</b>	<i>Break</i>		

	Hall A		Hall B
<b>14:45-16:15</b>	<b>Session 12: Paediatrics</b>	<b>14:45-16:15</b>	<b>Session 13: Lymphoma</b>
<b>14:45-15:30</b>	Controversy: Is TBI needed for allograft in ALL? Moderator: <b>Selim Corbacioglu</b> , Germany	<b>14:45-15:30</b>	Controversy: Are monoclonal antibodies as effective as CAR-T in R/R DLBCL? Moderator: <b>David Porter</b> , USA
14:45-15:00	Yes: <b>Christina Peters</b> , Austria	14:45-15:00	Yes: <b>Marion Subklewe</b> , Germany
15:00-15:15	No: <i>TBA</i>	15:00-15:15	No: <b>Francis Ayuk</b> , Germany
15:15-15:30	Discussion	15:15-15:30	Discussion
<b>15:30-16:15</b>	Controversy: Is haplo the alternative donor of choice for sickle cell anemia? Moderator: <b>Christina Peters</b> , Austria	<b>15:30-16:15</b>	Controversy: Do CAR-T-cells have a role in treatment of CLL? Moderator: <b>Robin Foa</b> , Italy
15:30-15:45	Yes: <b>Selim Corbacioglu</b> , Germany	15:30-15:45	Yes: <b>David Porter</b> , USA
15:45-16:00	No: <b>Josu De la Fuente</b> , UK	15:45-16:00	No: <i>TBA</i>
16:00-16:15	Discussion	16:00-16:15	Discussion
<b>16:15-16:30</b>	<i>Break</i>		
	Hall A		Hall B
<b>16:30-18:00</b>	<b>Session 14: COVID (I) and VOD</b>	<b>16:30-18:00</b>	<b>Session 15: Hodgkin lymphoma</b>
<b>16:30-17:15</b>	Controversy: Are patients after resolution of COVID-19 at higher risk after allogeneic SCT? Moderator: <b>Alessandro Rambaldi</b> , Italy	<b>16:30-17:15</b>	Controversy: Is there a role for Allo in HL? Moderator: <b>Norbert Schmitz</b> , Germany
16:30-16:45	Yes: <b>Per Ljungman</b> , Sweden	16:30-16:45	Yes: <b>Anna Sureda</b> , Spain
16:45-17:00	No: <b>Malgorzata Mikulska</b> , Italy	16:45-17:00	No: <b>Andreas Engert</b> , Germany
17:00-17:15	Discussion	17:00-17:15	Discussion
<b>17:15-18:00</b>	Controversy: Do we need new diagnostic criteria for VOD? Moderator: <b>Antonio Pagliuca</b> , UK	<b>17:15-18:00</b>	Controversy: Is Haplo the donor of choice in relapsing HL for allogeneic SCT? Moderator: <b>Michael Bishop</b> , USA
17:15-17:30	Yes: <b>Selim Corbacioglu</b> , Germany	17:15-17:30	Yes: <b>Didier Blaise</b> , France
17:30-17:45	No: <b>Rafael Duarte</b> , Spain	17:30-17:45	No: <b>Norbert Schmitz</b> , Germany
17:45-18:00	Discussion	17:45-18:00	Discussion
<b>18:00-19:00</b>	<i>COSTEM Virtual Poster Walk and Awards</i>		

Sunday, October 24

<b>09:30-11:00</b>	<b>Session 16: Cellular therapies I</b>
<b>09:30-10:15</b>	Controversy: Are dual CARs more effective?

09:30-09:45	Moderator: <b>Michael Hudecek</b> , Germany
09:45-10:00	Yes: <b>Nirali Shah</b> , USA
10:00-10:15	No: <b>Michael Bishop</b> , USA
	Discussion
<b>10:15-11:00</b>	Controversy: Are NK-CAR cells as effective as CAR-T-cells?
	Moderator: <b>Chiara Bonini</b> , Italy
10:15-10:30	Yes: <b>Ulrike Köhl</b> , Germany
10:30-10:45	No: <b>Michael Hudecek</b> , Germany
10:45-11:00	Discussion
<b>11:00-11:15</b>	<i>Break</i>
<b>11:15-12:45</b>	<b>Session 17: Cellular therapies II and COVID (II)</b>
<b>11:15-12:00</b>	Controversy: Are TCR engineering-based cell therapies the next buster in T-cell based immunotherapy?
	Moderator: <b>Michael Bishop</b> , USA
11:15-11:30	Yes: <b>Chiara Bonini</b> , Italy
11:30-11:45	No: <b>Christian Chabannon</b> , France
11:45-12:00	Discussion
<b>12:00-12:45</b>	Controversy: Is early COVID vaccination after allogeneic stem cell transplantation effective?
	Moderator: <b>Per Ljungman</b> , Sweden
12:00-12:15	Yes: <b>Rafael de la Cámara</b> , Spain
12:15-12:30	No: <i>TBA</i>
12:30-12:45	Discussion
<b>12:45-13:00</b>	Closing remarks <b>Nicolaus Kröger</b> , Germany; <b>Arnon Nagler</b> , Israel